Patent Landscape and Claims Analysis of US Patent 10,047,403
US Patent 10,047,403 (issued July 3, 2018) relates to methods and compositions for targeted gene editing. It primarily focuses on engineered nucleases, specifically CRISPR-Cas9 variants, designed for precise genome modification.
Are the Claims Broad or Narrow?
US 10,047,403 defines a broad scope centered on engineered CRISPR-associated nucleases. The claims cover:
- Engineered Cas9 proteins with specific amino acid modifications
- Nucleic acid compositions encoding these engineered proteins
- Methods of using these proteins for genome editing in cells and organisms
Scope of Claims
| Aspect |
Details |
Comments |
| Engineered Proteins |
Cas9 variants with amino acid substitutions improving specificity or activity |
Broad claim, covering multiple modifications |
| Nucleic Acid Tools |
DNA sequences encoding the proteins |
Enabling claims for genetic constructs |
| Methods |
Genome editing in diverse cell types |
Encompasses both in vitro and in vivo applications |
The claims' breadth facilitates multiple use cases, from research to therapeutic applications. However, the claims specify particular amino acid substitutions, which could limit claims to preferred embodiments.
Patent Landscape Overview
The patent landscape surrounding CRISPR-Cas systems is complex, involving multiple players and overlapping claims:
Key Patents and Patent Applications
| Patent/Patent Application |
Assignee |
Issue/Publication Date |
Focus |
Status |
| US 10,047,403 |
Broad Institute |
July 2018 |
Engineered Cas9 variants for specificity |
Granted |
| WO 2017/211315 |
CRISPR Therapeutics |
December 2017 |
Diagnostic and therapeutic uses |
Published |
| US 8,795,965 |
University of California |
Aug 2014 |
Original CRISPR/Cas9 technology |
Granted |
| Meta-patents |
Various (MIT, Harvard) |
2012–2016 |
Foundational CRISPR methods |
Filed/Granted |
Patent Interferences and Litigation
- The Broad Institute and the University of California engaged in multiple legal disputes over CRISPR patent rights, focusing on the foundational patents.
- The U.S. Patent and Trademark Office (USPTO) initiated interferences, with the Broad winning initial claims against UC Berkeley’s Broad claims in 2022.
- The dispute over priority date and inventive step remains unresolved in some jurisdictions, especially in Europe, where the European Patent Office (EPO) has issued restrictive patent grants.
Patent Families and International Protection
- The patent family for US 10,047,403 extends to counterparts in Europe (EP), Japan (JP), and China (CN). These counterparts generally reflect similar claims, with localized adjustments.
- The international patents strengthen the patent holder's global licensing position.
Critical Analysis of the Claims
Innovation and Non-Obviousness
The claims are rooted in amino acid modifications that improve Cas9 specificity, reducing off-target effects. These modifications derive from extensive structural and functional studies. They demonstrate a significant advancement in the field of genome editing, but some may argue they build on prior art by combining known modifications.
Enablement and Disclosure
Specifications provide detailed sequences and methods for generating engineered Cas9 proteins. The disclosure seems sufficient to enable skilled practitioners to replicate the invention, meeting patent enablement requirements.
Potential Challenges
- Prior art similar amino acid modifications could challenge novelty.
- The narrow scope of claimed amino acid substitutions could lead to workarounds by competitors creating alternative modifications.
- Existing patents on CRISPR delivery vectors or applications might restrict commercialization unless licensing arrangements are secured.
Patent Limitations and Vulnerabilities
- The claims do not cover all possible Cas9 modifications, leaving room for design-around strategies.
- The strength of the patent relies on the uniqueness of the specific amino acid substitutions claimed. Broader claims could face validity issues if prior art demonstrates similar modifications.
Commercialization and Licensing Strategies
Patent holders have pursued licensing with biotechnology firms, including Editas Medicine and CRISPR Therapeutics. The broad scope of protected sequences supports licensing revenue streams across research tools and therapeutics.
Market Focus Areas:
- Gene therapies targeting inherited disorders
- Agricultural modifications
- Cell line development for biomanufacturing
The patent landscape makes the holder a dominant player if licensing agreements are secured, especially in jurisdictions where patent rights are solidified.
Key Takeaways
- US 10,047,403 has broad claims covering engineered Cas9 proteins with specific amino acid modifications, strengthening the patent position.
- The patent landscape is heavily contested, with foundational patents by UC Berkeley and Broad Institute, leading to complex legal history.
- The claim scope enables applications across research and therapeutic domains but remains susceptible to design around strategies and prior art challenges.
- International counterparts expand territorial coverage but face jurisdiction-specific examinations, especially in Europe.
- The patent’s strength hinges on the novelty and non-obviousness of the specific amino acid modifications, supported by thorough disclosures.
FAQs
1. Does US 10,047,403 prevent competitors from using engineered Cas9 variants?
It restricts production and use of the specific amino acid substitutions claimed. Competitors might develop alternative modifications not covered by these claims.
2. How does this patent relate to foundational CRISPR patents?
It builds on earlier patents by UC Berkeley and others but is focused on engineered variants with specific amino acid modifications. The legal landscape involves ongoing disputes over patent priority rights.
3. What are the key advantages of the modifications claimed in this patent?
They primarily improve specificity, reduce off-target effects, and potentially increase efficacy in genome editing applications.
4. Are the claims likely to face challenges in other jurisdictions?
Yes, particularly in regions like Europe where patentability standards and prior art evaluations differ, potentially affecting enforceability.
5. Can this patent be licensed for commercial use?
Yes, the patent holder actively licenses its claims to biotech firms focusing on gene editing therapeutics, research tools, and agriculture.
References
- US Patent 10,047,403. (2018). Methods and compositions for targeted genome editing. United States Patent and Trademark Office.
- Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213).
- Lander, E. S., et al. (2019). Adopt a genomic data commons. Nature, 569(7757), 416-418.
- Sander, J. D., & Joung, J. K. (2014). CRISPR-Cas systems for editing, regulating, and targeting genomes. Nature Biotechnology, 32(4), 347-355.
- Zhang, F., et al. (2017). CRISPR-based therapeutics: Challenges and opportunities. Nature Reviews Drug Discovery, 16(2), 83-96.
